Mylan Faces Fight To Bar Generic Sleep Aid As Launch Nears

Law360, London (June 18, 2020, 8:24 PM BST) -- Neurim Pharmaceuticals urged an appeals court Thursday to grant an injunction blocking Mylan from selling a generic version of Neurim's patented insomnia treatment, with the drug giant poised to launch its generic rival product within 24 hours.

Counsel for the drug research and development company argued that a High Court judge wrongly dismissed Neurim's request for the injunction to prevent Mylan from putting its Circadin product on the market while Neurim pursues its patent litigation. A trial in the case is slated to begin at the end of October.

High Court Judge Marcus Smith didn't consider all the potential damage Neurim...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!